Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 18/20 | 0.52 |
| ▸ | PDE4A | P27815 | 1/20 | 0.52 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.52 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | HPGDS | O60760 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5840161 | 1.00 | PDE4B (0.52) | PDE4BPDE4APDE4DIRAK4CYP3A4 | |
| SCHEMBL5780787 | 0.90 | PDE4B (0.53) | PDE4BPDE4APDE4DCYP3A4 | |
| SCHEMBL5780784 | 0.90 | PDE4B (0.53) | PDE4BPDE4APDE4DCYP3A4 | |
| SCHEMBL8313084 | 0.89 | PDE4B (0.55) | PDE4BPDE4APDE4DCYP3A4 | |
| SCHEMBL5840683 | 0.89 | PDE4B (0.55) | PDE4BPDE4APDE4DCYP3A4 | |
| SCHEMBL5840694 | 0.89 | PDE4B (0.55) | PDE4BPDE4APDE4DCYP3A4 | |
| SCHEMBL5840169 | 0.89 | PDE4B (0.55) | PDE4BPDE4APDE4DCYP3A4 | |
| SCHEMBL5780660 | 0.89 | PDE4B (0.55) | PDE4BPDE4APDE4DCYP3A4 | |
| SCHEMBL5780663 | 0.89 | PDE4B (0.55) | PDE4BPDE4APDE4DCYP3A4 | |
| SCHEMBL5841990 | 0.89 | PDE4B (0.51) | PDE4BPDE4APDE4DCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7141586-B2 | Nicotinamide derivatives useful as PDE4 inhibitors | PFIZER INC. (US) | 2006-11-28 | — | — | US | disclosed |
| US-20050032838-A1 | Nicotinamide derivatives useful as PDE4 inhibitors | PFIZER INC. | 2005-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050032838-A1 | Nicotinamide derivatives useful as PDE4 inhibitors | CBR3, CBR1, PDE9A | PDE4B 8/4885PDE4A 6/4885PDE4D 72/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.